Dasatinib, marketed by Bristol Myers Squibb as Sprycel, is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. The synthesis of dasatinib involves multiple chemical steps, and patents protect its manufacturing processes.
How is Dasatinib Synthesized?
The synthesis of dasatinib typically involves the coupling of key chemical intermediates. One reported route involves the reaction of 2-chloro-6-methyl-N-(2-chloro-6-methylphenyl)pyrimidin-4-amine with 2-amino-N-(2-hydroxyethyl)thiazole-5-carboxamide, followed by further modifications and purification steps [2]. Patent literature often details specific reagents, reaction conditions, and purification methods to ensure the purity and yield of the active pharmaceutical ingredient.
When Does the Patent for Dasatinib Expire?
Patent expiration dates are crucial for the potential entry of generic versions of a drug. The exact expiration of patents for dasatinib and its manufacturing processes can be complex due to multiple patent filings covering different aspects of the drug, including composition of matter, methods of use, and synthesis. Information on specific patent expiry dates can be found through specialized patent databases, such as DrugPatentWatch.com [3].
Who Else Makes Dasatinib?
Currently, Bristol Myers Squibb is the originator of dasatinib (Sprycel) [1]. However, as patents expire or face challenges, other pharmaceutical companies may develop and seek approval for generic versions of dasatinib. The availability of generic alternatives depends on patent status and regulatory approvals in different regions.
Can Generic Dasatinib Be Made Before Patent Expiry?
Generally, generic versions of a drug cannot be legally manufactured or marketed before the relevant patents expire or are invalidated. However, legal challenges to patents, such as Paragraph IV certifications in the United States, can lead to earlier generic entry if successful. These processes allow generic manufacturers to assert that a patent is invalid or will not be infringed by their proposed product [4].
What Are the Risks Associated with Dasatinib?
Like all medications, dasatinib carries potential risks and side effects. Common side effects reported include diarrhea, rash, nausea, headache, fatigue, muscle pain, and myelosuppression (low blood cell counts) [1]. More serious side effects can include pleural effusion (fluid around the lungs), cardiac events, and bleeding [1]. Patients are advised to discuss all potential risks with their healthcare provider.
What Clinical Data Supports Dasatinib's Use?
Dasatinib's efficacy and safety have been established through numerous clinical trials. Key studies have demonstrated its effectiveness in patients with CML and Ph+ ALL, including those who are resistant or intolerant to other treatments [1]. Clinical data guides regulatory approvals and treatment guidelines for the drug.
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/sprycel-dasatinib-safety-information
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.fda.gov/drugs/abbreviated-new-drug-applications-and-505b2-applications/paragraph-iv-patent-notifications